HPLC, UHPLC
HLPC used in tobramycin study
Oct 20 2011
In a study published by Critical Care, a team from the Netherlands noted that tobramycin is one of the components used for selective decontamination of the digestive tract (SDD), applied to prevent colonisation and subsequent infections in critically ill patients.
Tobramycin is not normally absorbed into the body but the team hypothesised that the critical illness may cause a failure of the gut barrier, causing the components to be absorbed.
Using high performance liquid chromatography - mass spectrometry/mass spectrometry (HLPC-MS/MS), the scientists tested the blood and urine of 71 patients, once daily for seven days.
The team found that 99 per cent of those studied had at least one positive urine sample and 49 per cent had a urinary concentration greater than or equal to 1 mg/L.
"The majority of acute critically ill patients treated with enteral tobramycin as a component of SDD had traces of tobramycin in blood, especially those with severe shock, inflammation and subsequent acute kidney injury," the team concluded.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
May 05 2024 Seville, Spain
May 15 2024 Birmingham, UK
May 19 2024 Brno, Czech Republic
May 21 2024 Lagos, Nigeria
May 23 2024 Beijing, China